Trial · Interventional
Status unknownPhase 4Registry dataMethylene Blue and Ozone in Early Sepsis
Overview
- Status
- Status unknown
- Phase
- Phase 4
- Enrollment
- 40 participants (estimated)
- Sponsor
- Assiut University · Other
- Design
- Randomized · Double masking
- Countries
- Not stated
- Start
- Oct 2016
- Primary completion
- Mar 2017 (estimated)
- Completion
- Apr 2017 (estimated)
- First posted
- 22 Sept 2016 (estimated)
- Last update posted
- 22 Sept 2016 (estimated)
- Conditions
- Sepsis
Timeline
1 trial
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 4
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
effects of methylene blue and ozone O3 therapy effects in early sepsis management , and their implications upon outcome
Interventions
- methylene blueDrug
- ozoneDrug
- saline infusionOther
- oxygenOther
Arms2
Active comparator
M methylene blue and ozone
intravenous methylene blue and blood mixed with ozone ozone injection in early sepsis patients
Placebo comparator
P Placebo
saline and oxygen mixed blood injection in early sepsis patients
Primary outcomes1
Outcomes the sponsor listed as primary.
APACHE score
Time frame · 7 days
Secondary outcomes(1)
ICU stay
Time frame · 30 days
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
A trial that is still running, or that stopped early, may post results later.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- All
- Age
- from 18 Years up to 40 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.